LAWRENCE, Mass., June 18, 2015 /PRNewswire/ -- NxStage
Medical, Inc. (Nasdaq: NXTM) is encouraging patients to
take control of their dialysis therapy and consider home
hemodialysis in the wake of a new study that found patient
survivability rates are significantly higher with home hemodialysis
(HHD) than peritoneal dialysis (PD). The Incident Cohort Study, the
first of its size, was completed by the Australian and New Zealand
Dialysis and Transplantation Registry and shows that the five-year
survival rate for HHD is at 85 percent while the survival rate for
PD patients is just 44 percent. A leading manufacturer of dialysis
products, NxStage, believes the recent findings should inspire
dialysis patients to ask their healthcare providers about home
hemodialysis therapy with the System One. Currently, less than two
percent of dialysis patients in the U.S. are performing HHD, versus
approximately 9% performing PD.
"These data clearly show that excellent long-term survival can
be achieved in patients that are prescribed home hemodialysis
within 90 days of starting maintenance dialysis," said Dr.
Eric Weinhandl, epidemiologist and
lead investigator on multiple published studies on home dialysis
clinical outcomes as part of the Chronic Disease Research Group.
"Interestingly, the survival advantage of HHD over PD was evident
in multiple frames, including younger and older patients,
non-diabetics and diabetics, and early and late follow-up."
Historically, studies comparing clinical outcomes between
peritoneal dialysis and home hemodialysis have been limited. The
Incident Cohort Study was the largest of its kind and assessed all
Australian and New Zealand adult
patients receiving home dialysis on day 90 after initiation of
renal replacement therapy between 2000 and 2012. It included 10,710
patients on incident peritoneal dialysis and 706 patients on
incident home hemodialysis and found that the risk of
death-censored technique failure for HHD was 66 percent lower than
PD. Directionally, these results were very consistent with
recent presentations of survival and technique survival on NxStage
HHD patients vs. PD in the US published by Weinhandl at the 2014
ASN Renal Week and 2015 NKC Spring Clinical Meeting.
"This strong clinical data backs the efficacy of HHD and affirms
the results of recent studies," said NxStage President,
Joe Turk. "These results further
reinforce the need for clinicians to consider HHD as a first
strategy for incident patients, not just when PD fails."
To learn more about NxStage and the System One, please visit
NxStage.com.
Despite the health benefits that home hemodialysis may
provide to those with chronic kidney disease, this form of therapy
is not for everyone. The reported benefits of home hemodialysis may
not be experienced by all patients. The risks associated with
hemodialysis treatments in any environment include, but are not
limited to, high blood pressure, fluid overload, low blood
pressure, heart-related issues, and vascular access complications.
The medical devices used in hemodialysis therapies may add
additional risks including air entering the bloodstream and blood
loss due to clotting or accidental disconnection of the blood
tubing set. Certain risks are unique to the home. Treatments at
home are done without the presence of medical personnel and on-site
technical support. Patients and their partners must be trained on
what to do and how to get medical or technical help if
needed.
About the NxStage System One
The NxStage System One is
the first and only truly portable hemodialysis system cleared
specifically by the FDA for home hemodialysis and home
nocturnal hemodialysis. Its simplicity and revolutionary size (just
over a foot tall) are intended to allow convenient use in patients'
homes and give patients the freedom to travel with their therapy.
When combined with the NxStage PureFlow SL Dialysis Preparation
System, patients are able to further simplify, using ordinary tap
water to create dialysis fluid on demand. Unlike conventional
hemodialysis systems, the System One requires no special
infrastructure to operate. Under the guidance of their physician,
patients can use the NxStage System One, with their trained
partners, where, how and when it best meets their needs, including
while they are sleeping - at home or on vacation and at a medically
appropriate treatment frequency. http://www.nxstage.com/.
About NxStage Medical
NxStage Medical
Inc. (Nasdaq: NXTM) is a medical device company, headquartered
in Lawrence, Massachusetts,
USA, that develops, manufactures and markets innovative
products for the treatment of ESRD and acute kidney failure. For
more information on NxStage and its products, please visit the
Company's website at www.nxstage.com.
Forward-Looking Statements
This release
contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
contained in this release that are not clearly historical in nature
are forward-looking, and the words "anticipate," "believe,"
"expect," "estimate," "plan," and similar expressions are generally
intended to identify forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking
statements as a result of various important factors including those
that are discussed in NxStage's filings with the Securities
and Exchange Commission, including the Quarterly Report on Form
10-Q for the quarter ended March 31, 2015. NxStage is under no
obligation to (and expressly disclaims any such obligation to)
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
Media contact:
Kristen K. Sheppard, Esq.
ksheppard@nxstage.com
Tel: (978) 332-5923
Logo -
http://photos.prnewswire.com/prnh/20110503/MM94799LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/new-study-finds-home-hemodialysis-patient-survival-rates-nearly-double-those-of-peritoneal-dialysis-300101302.html
SOURCE NxStage Medical, Inc.